Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Curadim Pharma Co Ltd
Epigen Biosciences Inc
Horizon Therapeutics Plc
Novo Nordisk AS
RxBio Inc
Takeda Pharmaceutical Co Ltd
Ube Industries Ltd
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
BMS-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986278 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986337 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CP-2090 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EPGN-2154 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EPGN-696 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HL-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HZN-825 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-615 - Drug Profile
Product Description
Mechanism Of Action
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
Featured News & Press Releases
Jan 24, 2022: Horizon Therapeutics announces first patient enrolled in phase 2b pivotal trial evaluating HZN-825 for the treatment of idiopathic pulmory fibrosis (IPF)
Nov 09, 2021: Horizon Therapeutics announces first patient enrolled in phase 2b pivotal trial evaluating HZN-825 for the treatment of diffuse cutaneous systemic sclerosis
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Curadim Pharma Co Ltd, 2022
Pipeline by Epigen Biosciences Inc, 2022
Pipeline by Horizon Therapeutics Plc, 2022
Pipeline by Novo Nordisk AS, 2022
Pipeline by RxBio Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Ube Industries Ltd, 2022
Dormant Products, 2022